HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List

Stock News12-08

KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million.

On December 7, KEYMED BIO announced that its self-developed Class 1 innovative drug Kangyueda® (Sprifermin Injection) has been included in the National Reimbursement Drug List (NRDL) for 2025, which will take effect on January 1, 2026.

Kangyueda® (Sprifermin) is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China. It precisely inhibits type 2 inflammatory diseases by dual-blocking the IL-4/IL-13 signaling pathway.

Currently, Kangyueda® (Sprifermin) has been approved for three indications: moderate-to-severe atopic dermatitis in adults inadequately controlled by topical treatments, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate-to-severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids and antihistamines. All three indications have been included in the updated NRDL.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176519224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176519224","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List","media":"Stock News","content":"<p>KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million.</p>\n<p>On December 7, KEYMED BIO announced that its self-developed Class 1 innovative drug Kangyueda® (Sprifermin Injection) has been included in the National Reimbursement Drug List (NRDL) for 2025, which will take effect on January 1, 2026.</p>\n<p>Kangyueda® (Sprifermin) is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China. It precisely inhibits type 2 inflammatory diseases by dual-blocking the IL-4/IL-13 signaling pathway.</p>\n<p>Currently, Kangyueda® (Sprifermin) has been approved for three indications: moderate-to-severe atopic dermatitis in adults inadequately controlled by topical treatments, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate-to-severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids and antihistamines. All three indications have been included in the updated NRDL.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million.</p>\n<p>On December 7, KEYMED BIO announced that its self-developed Class 1 innovative drug Kangyueda® (Sprifermin Injection) has been included in the National Reimbursement Drug List (NRDL) for 2025, which will take effect on January 1, 2026.</p>\n<p>Kangyueda® (Sprifermin) is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China. It precisely inhibits type 2 inflammatory diseases by dual-blocking the IL-4/IL-13 signaling pathway.</p>\n<p>Currently, Kangyueda® (Sprifermin) has been approved for three indications: moderate-to-severe atopic dermatitis in adults inadequately controlled by topical treatments, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate-to-severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids and antihistamines. All three indications have been included in the updated NRDL.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"","article_id":"1176519224","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176519224","pubTimestamp":1765157433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million. On December 7, KEYMED BIO announced that its self-developed Class 1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","BK1574":"生物医药B类股","02162":"康诺亚-B","BK1583":"高瓴概念","BK1161":"生物科技"},"translate_title":"港股动向|康美生物-B(02162)高开超4%，斯普瑞明注射液纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million.\nOn December 7, KEYMED BIO announced that its self-developed Class 1 innovative drug Kangyueda® (Sprifermin Injection) has been included in the National Reimbursement Drug List (NRDL) for 2025, which will take effect on January 1, 2026.\nKangyueda® (Sprifermin) is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China. It precisely inhibits type 2 inflammatory diseases by dual-blocking the IL-4/IL-13 signaling pathway.\nCurrently, Kangyueda® (Sprifermin) has been approved for three indications: moderate-to-severe atopic dermatitis in adults inadequately controlled by topical treatments, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate-to-severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids and antihistamines. All three indications have been included in the updated NRDL.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176519224","isCrawlerRequest":true}